Dr. Di Nicola Massimo
Doctor
Contacts
- Mail: massimo.dinicola@istitutotumori.mi.it
- Tel: 0223902506
Specialty / Department
- Hematology
- Medical Oncology
Dr. Massimo Di Nicola conducts research in the field of translational medicine applied to oncology and onco-hematology, with extensive expertise in cellular and molecular biology. He graduated in Medicine and Surgery in 1987 and continued his training at prestigious clinical and research institutions before joining the National Cancer Institute in Milan in 1990.
From 2000 to 2006, he directed the Unit for Cryopreservation and Quality Control of Hematopoietic Stem Cells for Autologous Transplantation. Between 2006 and 2013, he served as Deputy Director of the Medical Oncology Division 2.
He is currently the Head of the Clinical Tumor Immunotherapy and Innovative Therapies Unit. Academically, he is a Contract Professor at the Specialization School in Medical Oncology and a Tutor in the Virgilio Program at the University of Milan, as well as a member of the PhD Program in Molecular Oncology and Immunology at the University of Chieti.
He is a co-inventor of two patents. Clinically, he has focused on the care of patients with hematologic diseases and solid tumors, using high-dose chemotherapy and autologous stem cell transplantation. He leads a research laboratory in tumor immunotherapy and coordinates Phase I and II clinical trials with innovative drugs.
He has contributed to the development of advanced therapeutic strategies, including high-dose chemotherapy, tumor vaccination and molecular targeted therapies. He is the author or co-author of over 160 scientific publications and is a member of several national and international scientific societies.
Development and application of adoptive immunotherapy:
a) Engineering of T lymphocytes (CART cells) through the expression of the variable fraction of antibody single chains (ScFv) capable of recognizing tumor antigens in an HLA-independent manner (Project “FORCE4CURE” in collaboration with 4 IRCCS in Lombardy; MOH Finalized Research Line 2);
b) Optimization of the processes of selection, expansion and reinfusion of autologous antitumor lymphocyte populations from peripheral blood for the development of an effective adoptive immunotherapy program in patients with solid tumors (MOH Finalized Research Line 2).
- Mail: massimo.dinicola@istitutotumori.mi.it
- Tel: 0223902506
Immunoterapia Clinica dei Tumori e Terapie Innovative
Oncologia Medica 1
Design, development and optimization of novel CAR T cells using Globo H as a target for solid tumors cell therapy
Design, development and optimization of novel CAR T cells using Globo H as a target for solid tumors cell therapy
Ex-vivo expansion of T cells obtained from tumor samples or from peripheral blood and reinfused in metastatic patients
Ex-vivo expansion of T cells obtained from tumor samples or from peripheral blood and reinfused in metastatic patients
Epigenetic events involved in CAR T cells maturation: new therapeutic combinations for solid tumors
Epigenetic events involved in CAR T cells maturation: new therapeutic combinations for solid tumors
Last update: 26/05/2025